Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SIDE-EFFECTS OF INHALED CORTICOSTEROIDS
Autore:
TOOGOOD JH;
Indirizzi:
UNIV WESTERN ONTARIO,LONDON HLTH SCI CTR,ALLERGY CLIN,S CAMPUS VICTORIA,800 COMMISSIONERS RD E LONDON ON N6A 4G5 CANADA
Titolo Testata:
Journal of allergy and clinical immunology
fascicolo: 5, volume: 102, anno: 1998,
pagine: 705 - 713
SICI:
0091-6749(1998)102:5<705:SOIC>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
BONE-MINERAL DENSITY; POSTERIOR SUBCAPSULAR CATARACTS; DECREASES SERUM OSTEOCALCIN; ACUTE ADRENAL INSUFFICIENCY; LONG-TERM TREATMENT; ASTHMATIC-CHILDREN; BECLOMETHASONE DIPROPIONATE; ORAL PREDNISOLONE; FLUTICASONE PROPIONATE; COLLAGEN TURNOVER;
Keywords:
ASTHMA; INHALED STEROIDS; SIDE EFFECTS; ADRENOCORTICAL SUPPRESSION; CATARACT; GLAUCOMA; GROWTH; OSTEOPOROSIS; INFECTION; OROPHARYNX COMPLICATIONS; SKIN ATROPHY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
97
Recensione:
Indirizzi per estratti:
Citazione:
J.H. Toogood, "SIDE-EFFECTS OF INHALED CORTICOSTEROIDS", Journal of allergy and clinical immunology, 102(5), 1998, pp. 705-713

Abstract

Inhaled corticosteroid (ICS) therapy carries less risk of complicating drug- or disease-related morbidity and mortality than that associated with other antiasthmatic drugs such as prednisone, theophylline, or beta(2)-agonist bronchodilators. Serious side effects are uncommon, but the risk increases with the daily dose. The degree of risk is most effectively minimized by ensuring each patient uses the smallest daily dose sufficient to maintain optimum control of their disease. Any patient in whom ocular symptoms develop while receiving ICS therapy shouldpromptly be evaluated by an eye specialist. Growth, velocity is commonly reduced during ICS therapy and should he monitored routinely. Bonemetabolism may be affected by ion or medium doses of ICS, but there is no evidence such doses cause osteoporosis or fracture, High-dose therapy may. reduce hone density and increase the risk of fracture, particularly if other risk factors for osteoporosis are present. Research is needed to better define the impact of ICS therapy in children on height and peak hone density. attained at maturity, Also, there is a needfor practice guidelines specifically applicable to the prevention of bone loss during ICS treatment.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/09/20 alle ore 18:52:37